SUNNYVALE, Calif., July 18, 2012 /PRNewswire/ -- IntraOp Medical Corporation (OTC: IOPD.PK - News) installed the 10th of the next generation Mobetrons last week at Helios-Kliniken (helios-kliniken.de) in Berlin Germany. The Mobetron is used for electron IORT (IOERT), which has demonstrated the best overall clinical results of any breast cancer treatment, resulting in 10 year recurrence rates as low as 1%. Currently each Mobetron in Germany treats between 250-350 breast cancer patients per year with IOERT. Many of these patients are also eligible for oncoplastic reconstruction which eliminates the need for additional cosmetic surgery and speeds the process of "emotional reconstruction". Germany is a leader of evidence based medicine. The rapid adoption of IOERT for breast cancer treatment is immediately allowing thousands of women with breast cancer to achieve better results and cosmesis, over a shorter treatment course. IOERT provides the treatment flexibility to accommodate nearly all breast patients including younger pre-menopausal patients.
"IOERT is becoming the gold standard in the successful treatment of cancer," says Ernesto G. Lanzotti, Director of MD51 Germany GmbH, IntraOp Medical European distributor. "We are very proud to start cooperating with Helios Kliniken because we understand the importance from both a treatment and medical science aspect and Helios-Kliniken is a leader in this regard."
The next generation Mobetron has also added a new benefit to the environment as well. The Mobetron provides radiation therapy (RT) more efficiently than any other RT technique, using less time, less energy, and producing little to no waste. The Mobetron can deliver a complete course of radiation therapy for select breast cancer candidates in 2 minutes using less than one tenth of a kilowatt hour (kWh) of electricity. The same treatment using conventional external beam radiation therapy requires 90 minutes of treatment (beam) over 30 days and uses over 100 kWh's for treatment and cooling.
The Mobetron is a true linear accelerator and generates only the radiation it needs for a given treatment without having to use active radioactive radiation sources. The Mobetron does not use disposable applicators like some of the other methods to treat cancers Intra-Operatively. This is effective for reducing both cost and waste. The Healthcare industry is the second largest producer of waste behind the food service industry and this will continue to be an area of great attention. "Eventually, policy will be enacted to discourage waste as seen in other industries, and we want to help lead this initiative," said John Powers, IntraOp Medical's CEO. For these reasons it is no surprise that the Mobetron is gaining more attention worldwide with Mobetrons recently shipping to new markets in Saudi Arabia and Turkey.
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer IOERT safely and effectively for all cancer patients. The Mobetron is the first IOERT device designed for use in existing operating rooms and has been used to treat over 20 different cancer indications. Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and happier patients with fewer side effects. Leading hospitals and clinics throughout the world use the Mobetron as a vital part of their comprehensive cancer program. For more information email firstname.lastname@example.org or call 408-636-1020 x128.
The HELIOS Hospital Group ranks among the largest and most medically advanced hospital groups in Germany. Since 2005 HELIOS is part of the global healthcare provider Fresenius Fresenius SE & Co.KGaA.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.
SOURCE IntraOp Medical Corporation